NO20072179L - Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer - Google Patents

Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer

Info

Publication number
NO20072179L
NO20072179L NO20072179A NO20072179A NO20072179L NO 20072179 L NO20072179 L NO 20072179L NO 20072179 A NO20072179 A NO 20072179A NO 20072179 A NO20072179 A NO 20072179A NO 20072179 L NO20072179 L NO 20072179L
Authority
NO
Norway
Prior art keywords
inhibitor
combination
bcr
treatment
proliferative diseases
Prior art date
Application number
NO20072179A
Other languages
English (en)
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20072179L publication Critical patent/NO20072179L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En kombinasjon og metoder er beskrevet som er anvendelige for behandling av kreft og/eller leukemi.
NO20072179A 2004-11-04 2007-04-27 Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer NO20072179L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62493704P 2004-11-04 2004-11-04
US63212204P 2004-12-01 2004-12-01
US64972205P 2005-02-03 2005-02-03
US70362805P 2005-07-29 2005-07-29
PCT/US2005/040145 WO2006052810A2 (en) 2004-11-04 2005-11-04 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
NO20072179L true NO20072179L (no) 2007-05-31

Family

ID=36337059

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072179A NO20072179L (no) 2004-11-04 2007-04-27 Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer

Country Status (13)

Country Link
US (2) US20060094728A1 (no)
EP (1) EP1812432A4 (no)
JP (1) JP2008519049A (no)
KR (1) KR20070073864A (no)
AR (1) AR053984A1 (no)
AU (1) AU2005304863A1 (no)
BR (1) BRPI0515721A (no)
CA (1) CA2586649A1 (no)
MX (1) MX2007005115A (no)
NO (1) NO20072179L (no)
RU (1) RU2007120710A (no)
TW (1) TW200628156A (no)
WO (1) WO2006052810A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302788B6 (cs) * 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
ATE505192T1 (de) * 2005-06-09 2011-04-15 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
WO2007047919A2 (en) 2005-10-20 2007-04-26 University Of South Florida Treatment of restenosis and stenosis with dasatinib
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR20100058660A (ko) * 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
CN102643275B (zh) * 2011-02-21 2016-04-20 江苏先声药物研究有限公司 一种达莎替尼n-6晶型新的制备方法
CN104788446A (zh) * 2011-06-24 2015-07-22 南京圣和药业股份有限公司 无水达沙替尼的制备及精制方法
AU2015212341A1 (en) * 2014-02-03 2016-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of Casein kinase I inhibitors for depleting stem cells
WO2024097804A1 (en) 2022-11-02 2024-05-10 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CZ302788B6 (cs) * 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
ATE479667T1 (de) * 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
CA2554201C (en) * 2004-01-21 2015-04-14 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Also Published As

Publication number Publication date
EP1812432A2 (en) 2007-08-01
MX2007005115A (es) 2007-06-26
US20060094728A1 (en) 2006-05-04
US20090093495A1 (en) 2009-04-09
WO2006052810A3 (en) 2007-02-08
WO2006052810A2 (en) 2006-05-18
JP2008519049A (ja) 2008-06-05
KR20070073864A (ko) 2007-07-10
RU2007120710A (ru) 2008-12-10
AU2005304863A1 (en) 2006-05-18
EP1812432A4 (en) 2009-11-25
BRPI0515721A (pt) 2008-08-05
AR053984A1 (es) 2007-05-30
TW200628156A (en) 2006-08-16
CA2586649A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
TW200801008A (en) Protein kinase inhibitors
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
MX346379B (es) Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.
NO20062885L (no) Terapeufiske anti-IGFR1-antistoffkombinasjoner
ATE445398T1 (de) Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
NO20070782L (no) Tetrapeptidanaloger.
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
NO20084749L (no) Organiske forbindelser og deres anvendelser
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application